Compare TV & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TV | OGN |
|---|---|---|
| Founded | 1969 | 1923 |
| Country | Mexico | United States |
| Employees | 26551 | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | N/A | 2020 |
| Metric | TV | OGN |
|---|---|---|
| Price | $2.89 | $13.29 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 5 |
| Target Price | $5.30 | ★ $11.40 |
| AVG Volume (30 Days) | 1.5M | ★ 14.9M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.83% | 0.60% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.72 |
| Revenue | N/A | ★ $6,216,000,000.00 |
| Revenue This Year | N/A | $0.45 |
| Revenue Next Year | N/A | $1.67 |
| P/E Ratio | ★ N/A | $18.42 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.67 | $5.69 |
| 52 Week High | $3.49 | $13.39 |
| Indicator | TV | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 43.11 | 78.82 |
| Support Level | $2.86 | $6.31 |
| Resistance Level | $2.94 | N/A |
| Average True Range (ATR) | 0.14 | 0.53 |
| MACD | -0.03 | 0.46 |
| Stochastic Oscillator | 21.95 | 98.00 |
Televisa is one of the leading telecom firms in Mexico. Its cable arm, Izzi, holds networks that pass 20 million Mexican homes and provide broadband service to nearly 6 million customers. The firm is also one of the largest pay-television providers in Mexico, with nearly 4 million customers. Televisa owns Sky Mexico, the country's only satellite-TV provider, serving about 4 million customers. After merging its traditional media business into Univision, Grupo Televisa owns a 43% stake in the combined entity TelevisaUnivision. Grupo Televisa spun off several smaller businesses, including magazine publishing, three of Mexico's professional soccer teams, and Azteca Stadium in February 2024, under the name Ollamani.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.